Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

201824 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier, NCT01445769 . Registered September 23, 2011.

Good health and well-being

Published in: Journal of Hematology & Oncology

Volume 11, Issue 1, pp. 101-101

Field-Weighted Citation Impact: 1.75